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Abstract
© MacKenzie et al. 2015. Recent clinical studies show that tyrosine kinase inhibitors slow the
rate of lung function decline and decrease the number of acute exacerbations in patients with
Idiopathic Pulmonary Fibrosis (IPF). However, in the murine bleomycin model of fibrosis, not all
tyrosine kinase signaling is detrimental. Exogenous ligands Fibroblast Growth Factor (FGF) 7 and
10 improve  murine  lung  repair  and  increase  survival  after  injury  via  tyrosine  kinase  FGF
receptor 2b-signaling. Therefore, the level and location of FGF/FGFR expression as well as the
exogenous effect of the most highly expressed FGFR2b ligand, FGF1, was analyzed on human
lung fibroblasts. Methods: FGF ligand and receptor expression was evaluated in donor and IPF
whole lung homogenates using western blotting and qPCR. Immunohistochemistry for FGF1 and
FGFR1/2/3/4 were performed on human lung tissue. Lastly, the effects of FGF1, a potent, multi-
FGFR ligand, were studied on primary cultures of IPF and non-IPF donor fibroblasts. Western
blots for pro-fibrotic markers, proliferation, FACS for apoptosis, transwell assays and MetaMorph
analyses on cell cultures were performed. Results: Whole lung homogenate analyses revealed
decreased FGFR b-isoform expression, and an increase in FGFR c-isoform expression. Of the
FGFR2b-ligands, FGF1 was the most significantly increased in IPF patients; downstream targets
of  FGF-signaling,  p-ERK1/2 and p-AKT were also increased.  Immunohistochemistry revealed
FGF1  co-localization  within  basal  cell  sheets,  myofibroblast  foci,  and  Surfactant  protein-C
positive alveolar epithelial type-II cells as well as co-localization with FGFR1, FGFR2, FGFR3,
FGFR4 and myofibroblasts  expressing the migratory marker  Fascin.  Both alone and in the
presence of heparin, FGF1 led to increased MAPK-signaling in primary lung fibroblasts. While
smooth  muscle  actin  was  unchanged,  heparin+FGF1 decreased collagen production  in  IPF
fibroblasts. In addition, FGF1+heparin increased apoptosis and cell migration. The FGFR inhibitor
(PD173074)  attenuated  these  effects.  Conclusions:  Strong  expression  of  FGF1/FGFRs  in
pathogenic regions of IPF suggest that aberrant FGF1-FGFR signaling is increased in IPF patients
and may contribute to the pathogenesis of lung fibrosis by supporting fibroblast migration and
increased MAPK-signaling.
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